Experimental Tango drug and Rasonque reportedly led to tumor responses in 82% of trial patients with a type of advanced pancreatic cancer

A trial of an experimental Tango Therapeutics drug with Revolution Medicines’ Rasonque yielded tumor responses in 82% of patients with a particular type of advanced pancreatic cancer, STAT’s Adam Feuerstein reports. At nine months, 88% were still alive without tumor progression; the regimen uses no chemotherapy. Those percentages do not establish that it works better than single-drug treatment or chemotherapy.